Causal AI is transforming the Pharma Business Model
Success rates, especially in Phase II, when efficacy is tested for the first time, are below 30 percent. Causal AI enables the prediction of clinical efficacy, thus making clinical development more cost-effective and changing the pharma business model. The pursuit of a single blockbuster molecule with annual sales of one billion dollars is being replaced by several molecules with lower revenue potential but equal profitability.
Speaker
Dr. Marco Schmidt
Co-founder and Chief Scientific Officer
biotx.ai
Sign-up
